4 Firms Steer Gilead's €1.45B Deal For Germany's MYR
Gilead Sciences will pay up to €1.45 billion ($1.76 billion) for German-based hepatitis D treatment developer MYR GmbH, the companies said Thursday, in a deal that was guided by four law...To view the full article, register now.
Already a subscriber? Click here to view full article